Fiona Maxwell

867 total citations
23 papers, 539 citations indexed

About

Fiona Maxwell is a scholar working on Oncology, Cancer Research and Surgery. According to data from OpenAlex, Fiona Maxwell has authored 23 papers receiving a total of 539 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 7 papers in Cancer Research and 5 papers in Surgery. Recurrent topics in Fiona Maxwell's work include Pancreatic and Hepatic Oncology Research (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Genomics and Diagnostics (6 papers). Fiona Maxwell is often cited by papers focused on Pancreatic and Hepatic Oncology Research (14 papers), Lung Cancer Research Studies (10 papers) and Cancer Genomics and Diagnostics (6 papers). Fiona Maxwell collaborates with scholars based in United States, Spain and United Kingdom. Fiona Maxwell's co-authors include Rohit Lal, Daniel C. Christoph, D. Ferry, T. Benepal, J. Cadranel, Carla Visseren‐Grul, Mayukh Das, Yvonne Summers, Donald C. McMillan and Tanios Bekaii‐Saab and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and British Journal of Cancer.

In The Last Decade

Fiona Maxwell

22 papers receiving 534 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fiona Maxwell United States 9 244 228 150 98 53 23 539
Hanan Ahmed Wahba Egypt 8 238 1.0× 226 1.0× 140 0.9× 94 1.0× 42 0.8× 24 529
Hend Ahmed El-Hadaad Egypt 9 243 1.0× 241 1.1× 140 0.9× 105 1.1× 36 0.7× 25 552
Guoxian Long China 15 291 1.2× 289 1.3× 217 1.4× 108 1.1× 34 0.6× 35 661
Katarzyna Aleksandra Kujawa Poland 9 246 1.0× 414 1.8× 242 1.6× 88 0.9× 80 1.5× 14 816
Fatemeh Rezaei‐Tazangi Iran 12 121 0.5× 277 1.2× 129 0.9× 69 0.7× 32 0.6× 55 572
Xiaoyi Zhang China 12 230 0.9× 161 0.7× 90 0.6× 66 0.7× 36 0.7× 38 487
Nita Fisher United Kingdom 8 181 0.7× 237 1.0× 156 1.0× 69 0.7× 28 0.5× 9 520
Christian Henninger Germany 15 265 1.1× 246 1.1× 104 0.7× 75 0.8× 97 1.8× 22 646

Countries citing papers authored by Fiona Maxwell

Since Specialization
Citations

This map shows the geographic impact of Fiona Maxwell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fiona Maxwell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fiona Maxwell more than expected).

Fields of papers citing papers by Fiona Maxwell

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fiona Maxwell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fiona Maxwell. The network helps show where Fiona Maxwell may publish in the future.

Co-authorship network of co-authors of Fiona Maxwell

This figure shows the co-authorship network connecting the top 25 collaborators of Fiona Maxwell. A scholar is included among the top collaborators of Fiona Maxwell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fiona Maxwell. Fiona Maxwell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Abdelrahim, Maen, Gazala Khan, Hassan Hatoum, et al.. (2025). Impact of UGT1A1*28 polymorphism on tolerability in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with NALIRIFOX in NAPOLI 3.. Journal of Clinical Oncology. 43(4_suppl). 717–717. 1 indexed citations
3.
4.
Hussein, Maen, Gazala Khan, Sreenivasa R Chandana, et al.. (2024). NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naïve patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): Updated overall survival analysis with 29-month follow-up of NAPOLI 3.. Journal of Clinical Oncology. 42(16_suppl). 4136–4136. 2 indexed citations
5.
6.
Chandana, Sreenivasa R, et al.. (2023). Risk factors for early-onset pancreatic ductal adenocarcinoma: A systematic literature review. European Journal of Cancer. 198. 113471–113471. 12 indexed citations
7.
Wainberg, Zev A., Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2021). First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study. European Journal of Cancer. 151. 14–24. 31 indexed citations
8.
Brendel, Karl, Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2021). Population pharmacokinetics of liposomal irinotecan in patients with cancer and exposure–safety analyses in patients with metastatic pancreatic cancer. CPT Pharmacometrics & Systems Pharmacology. 10(12). 1550–1563. 10 indexed citations
9.
Sachdev, Jasgit C., Pamela N. Münster, Donald W. Northfelt, et al.. (2020). Phase I study of liposomal irinotecan in patients with metastatic breast cancer: findings from the expansion phase. Breast Cancer Research and Treatment. 185(3). 759–771. 33 indexed citations
10.
Dean, Andrew, Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2020). 191P First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Results from a phase I/II study. Annals of Oncology. 31. S1313–S1314. 1 indexed citations
11.
Wainberg, Zev A., Tanios Bekaii‐Saab, Patrick M. Boland, et al.. (2020). LBA-1 First-line liposomal irinotecan + 5 fluorouracil/leucovorin + oxaliplatin in patients with pancreatic ductal adenocarcinoma: Long-term follow-up results from a phase 1/2 study. Annals of Oncology. 31. S241–S241. 3 indexed citations
12.
13.
Dayyani, Farshid, Patrick M. Boland, Andrew Dean, et al.. (2019). Abstract B14: CA 19-9 levels in patients with metastatic pancreatic adenocarcinoma receiving first-line therapy with liposomal irinotecan plus 5-fluorouracil/leucovorin and oxaliplatin (NAPOX). Cancer Research. 79(24_Supplement). B14–B14. 1 indexed citations
14.
Macarulla, Teresa, Karl Brendel, Christopher H. Lieu, et al.. (2019). Integrated population pharmacokinetic modelling of liposomal irinotecan in patients with various tumour types, including untreated metastatic pancreatic cancer (mPC). Annals of Oncology. 30. v263–v263. 2 indexed citations
15.
Anders, Carey K., Pamela N. Münster, Donald W. Northfelt, et al.. (2019). TRLS-06. PHASE 1 EXPANSION STUDY OF IRINOTECAN LIPOSOME INJECTION (nal-IRI) IN PATIENTS WITH METASTATIC BREAST CANCER (mBC): FINDINGS FROM THE COHORT WITH ACTIVE BRAIN METASTASIS (BM). Neuro-Oncology Advances. 1(Supplement_1). i9–i9. 1 indexed citations
16.
Summers, Yvonne, J. Cadranel, T. Benepal, et al.. (2016). Cisplatin in the modern era: The backbone of first-line chemotherapy for non-small cell lung cancer. Cancer Treatment Reviews. 44. 42–50. 311 indexed citations
17.
Maxwell, Fiona, et al.. (2015). Diagnostic strategy for the assessment of axillary lymph node status in breast cancer. Diagnostic and Interventional Imaging. 96(10). 1089–1101. 31 indexed citations
18.
Roxburgh, Campbell S.D., J E M Crozier, Fiona Maxwell, et al.. (2009). Comparison of tumour-based (Petersen Index) and inflammation-based (Glasgow Prognostic Score) scoring systems in patients undergoing curative resection for colon cancer. British Journal of Cancer. 100(5). 701–706. 61 indexed citations
19.
Maxwell, Fiona, et al.. (2004). Seizures and a hiccup in the diagnosis. Journal of Paediatrics and Child Health. 40(12). 707–708. 6 indexed citations
20.
Gunn, I R, Fiona Maxwell, Dairena Gaffney, Alex D. McMahon, & Chris J. Packard. (2004). Haemochromatosis gene mutations and risk of coronary heart disease: a west of Scotland coronary prevention study (WOSCOPS) substudy. Heart. 90(3). 304–306. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hanan Ahmed Wahba Breakdown of academic impact, for papers by Hend Ahmed El-Hadaad Breakdown of academic impact, for papers by Guoxian Long Breakdown of academic impact, for papers by Katarzyna Aleksandra Kujawa Breakdown of academic impact, for papers by Fatemeh Rezaei‐Tazangi Breakdown of academic impact, for papers by Xiaoyi Zhang Breakdown of academic impact, for papers by Nita Fisher Breakdown of academic impact, for papers by Christian Henninger
Rankless by CCL
2026